JP2018505139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505139A5 JP2018505139A5 JP2017530742A JP2017530742A JP2018505139A5 JP 2018505139 A5 JP2018505139 A5 JP 2018505139A5 JP 2017530742 A JP2017530742 A JP 2017530742A JP 2017530742 A JP2017530742 A JP 2017530742A JP 2018505139 A5 JP2018505139 A5 JP 2018505139A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- intracellular
- signaling domain
- cell signaling
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 230000005754 cellular signaling Effects 0.000 claims 13
- 230000003834 intracellular effect Effects 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102100027207 CD27 antigen Human genes 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 238000003259 recombinant expression Methods 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088882P | 2014-12-08 | 2014-12-08 | |
| US62/088,882 | 2014-12-08 | ||
| PCT/US2015/025047 WO2016093878A1 (en) | 2014-12-08 | 2015-04-09 | Anti-cd70 chimeric antigen receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020109158A Division JP7128860B2 (ja) | 2014-12-08 | 2020-06-24 | 抗ｃｄ７０キメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505139A JP2018505139A (ja) | 2018-02-22 |
| JP2018505139A5 true JP2018505139A5 (enExample) | 2018-05-24 |
| JP6724009B2 JP6724009B2 (ja) | 2020-07-15 |
Family
ID=52997584
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530742A Active JP6724009B2 (ja) | 2014-12-08 | 2015-04-09 | 抗ｃｄ７０キメラ抗原受容体 |
| JP2020109158A Active JP7128860B2 (ja) | 2014-12-08 | 2020-06-24 | 抗ｃｄ７０キメラ抗原受容体 |
| JP2022092594A Active JP7574243B2 (ja) | 2014-12-08 | 2022-06-07 | 抗ｃｄ７０キメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020109158A Active JP7128860B2 (ja) | 2014-12-08 | 2020-06-24 | 抗ｃｄ７０キメラ抗原受容体 |
| JP2022092594A Active JP7574243B2 (ja) | 2014-12-08 | 2022-06-07 | 抗ｃｄ７０キメラ抗原受容体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10689456B2 (enExample) |
| EP (3) | EP3230310B1 (enExample) |
| JP (3) | JP6724009B2 (enExample) |
| CN (2) | CN107207616B (enExample) |
| AU (3) | AU2015361261B2 (enExample) |
| DK (1) | DK3597663T3 (enExample) |
| ES (2) | ES2745153T3 (enExample) |
| PL (1) | PL3230310T3 (enExample) |
| PT (1) | PT3230310T (enExample) |
| SI (1) | SI3230310T1 (enExample) |
| WO (1) | WO2016093878A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3230310B1 (en) * | 2014-12-08 | 2019-06-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd70 chimeric antigen receptors |
| CN105949325B (zh) * | 2016-07-08 | 2019-07-16 | 重庆精准生物技术有限公司 | 包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用 |
| EP3344263A4 (en) * | 2016-08-04 | 2020-07-01 | Memorial Sloan-Kettering Cancer Center | CANCER ANTIGEN TARGETS AND USES THEREOF |
| US11788093B2 (en) | 2017-09-07 | 2023-10-17 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptor t-cells expressing interleukin-8 receptor |
| GB201720949D0 (en) * | 2017-12-15 | 2018-01-31 | Autolus Ltd | Cell |
| MX2020008184A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| US20200063100A1 (en) * | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| AU2019314452B2 (en) * | 2018-08-02 | 2022-12-08 | Kite Pharma, Inc | Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof |
| CN109880802B (zh) * | 2018-11-30 | 2022-12-13 | 北京美康基免生物科技有限公司 | 一种基于cd19和cd70的双重嵌合抗原受体基因修饰的免疫细胞及其应用 |
| MX2021013351A (es) * | 2019-04-30 | 2022-01-31 | Memorial Sloan Kettering Cancer Center | Terapias de combinacion. |
| US20200384278A1 (en) * | 2019-06-04 | 2020-12-10 | Jerome Canady Research Institute for Advanced Biological and Technological Sciences | Method for Combination Cold Atmospheric Plasma and CAR-T Therapy |
| EP4031150A4 (en) * | 2019-09-16 | 2023-11-01 | The General Hospital Corporation | CD70-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF |
| BR112022013445A2 (pt) * | 2020-01-08 | 2022-09-13 | Univ Texas | Método de modificação de células exterminadoras naturais para direcionar tumores cd70-positivos |
| CN111909966B (zh) * | 2020-04-01 | 2021-09-21 | 苏州克睿基因生物科技有限公司 | 一种制备经修饰的免疫细胞的方法 |
| CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| US20240024475A1 (en) * | 2020-12-01 | 2024-01-25 | Cure Genetics Co., Ltd | Antigen-Binding Protein Targeting CD70 and Use Thereof |
| US20240115606A1 (en) | 2020-12-15 | 2024-04-11 | Universiteit Antwerpen | Cell-Based Therapeutics Targeting CD70 |
| KR20230136184A (ko) * | 2021-01-25 | 2023-09-26 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Cd70-양성 종양을 표적화하기 위한 cd27-세포외 도메인 car |
| US20220378829A1 (en) * | 2021-05-12 | 2022-12-01 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating solid tumors |
| WO2023072307A1 (zh) * | 2021-10-25 | 2023-05-04 | 重庆精准生物技术有限公司 | 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用 |
| JP2025504501A (ja) * | 2022-01-19 | 2025-02-12 | 上海恒潤達生生物科技股▲フン▼有限公司 | 抗ｃｄ７０ナノボディ及びその応用 |
| EP4504222A4 (en) * | 2022-04-07 | 2026-04-15 | Univ Texas | METHODS FOR ACTIVATING AND EXPANDING MODIFIED NATURAL KILLER CELLS AND COMBINATIONS WITH ANTIBODIES |
| CN117126856A (zh) * | 2022-05-20 | 2023-11-28 | 上海雅科生物科技有限公司 | 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026024685A1 (en) * | 2024-07-23 | 2026-01-29 | Feromics Inc. | Uses of immunomodulatory fusion proteins to enhance efficacy of car-expressing immune effector cells |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU658370B2 (en) | 1990-07-13 | 1995-04-13 | General Hospital Corporation, The | CD53 cell surface antigen and use thereof |
| US7285267B2 (en) * | 1997-01-14 | 2007-10-23 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6α & 6β |
| US20070037165A1 (en) * | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| JP5934099B2 (ja) | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用 |
| CA2816379A1 (en) * | 2010-10-27 | 2012-05-03 | Baylor College Of Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP3459560B1 (en) * | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| JP6267644B2 (ja) * | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| CA3285826A1 (en) * | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| US9598489B2 (en) * | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| KR20210090298A (ko) * | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
| CN104177499B (zh) * | 2013-05-27 | 2019-01-08 | 上海雅科生物科技有限公司 | 一种嵌合抗原受体、编码基因、表达载体及其应用 |
| EP3230310B1 (en) * | 2014-12-08 | 2019-06-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd70 chimeric antigen receptors |
-
2015
- 2015-04-09 EP EP15718065.4A patent/EP3230310B1/en active Active
- 2015-04-09 SI SI201530869T patent/SI3230310T1/sl unknown
- 2015-04-09 PT PT15718065T patent/PT3230310T/pt unknown
- 2015-04-09 WO PCT/US2015/025047 patent/WO2016093878A1/en not_active Ceased
- 2015-04-09 CN CN201580066498.4A patent/CN107207616B/zh active Active
- 2015-04-09 US US15/531,626 patent/US10689456B2/en active Active
- 2015-04-09 AU AU2015361261A patent/AU2015361261B2/en active Active
- 2015-04-09 DK DK19178931.2T patent/DK3597663T3/da active
- 2015-04-09 ES ES15718065T patent/ES2745153T3/es active Active
- 2015-04-09 PL PL15718065T patent/PL3230310T3/pl unknown
- 2015-04-09 EP EP19178931.2A patent/EP3597663B1/en active Active
- 2015-04-09 JP JP2017530742A patent/JP6724009B2/ja active Active
- 2015-04-09 ES ES19178931T patent/ES2921208T3/es active Active
- 2015-04-09 EP EP22164990.8A patent/EP4043487A1/en active Pending
- 2015-04-09 CN CN202111253336.5A patent/CN113968913A/zh active Pending
-
2020
- 2020-06-10 AU AU2020203836A patent/AU2020203836B2/en active Active
- 2020-06-19 US US16/906,061 patent/US11999796B2/en active Active
- 2020-06-24 JP JP2020109158A patent/JP7128860B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277627A patent/AU2021277627B2/en active Active
-
2022
- 2022-06-07 JP JP2022092594A patent/JP7574243B2/ja active Active
-
2024
- 2024-05-14 US US18/663,557 patent/US20240294665A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502512A5 (enExample) | ||
| JP2014534207A5 (enExample) | ||
| JP2018531014A5 (enExample) | ||
| JP2018529380A5 (enExample) | ||
| BR112014008849A2 (pt) | receptores quiméricos de antígeno anti-cd22 | |
| JP2017537622A5 (enExample) | ||
| JP2020529841A5 (enExample) | ||
| JP2018064568A5 (enExample) | ||
| Kukkonen et al. | L protein, the RNA-dependent RNA polymerase of hantaviruses | |
| Gallichotte et al. | A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies | |
| Yip et al. | Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus | |
| MX384919B (es) | Receptores de células t de kras anti-mutado. | |
| Addetia et al. | SARS-CoV-2 ORF6 disrupts bidirectional nucleocytoplasmic transport through interactions with Rae1 and Nup98 | |
| JP2016532693A5 (enExample) | ||
| Kalveram et al. | Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR | |
| JP2020519298A5 (enExample) | ||
| SA518391109B1 (ar) | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ | |
| JP2017529851A5 (enExample) | ||
| JP2014500002A5 (enExample) | ||
| JP2019528769A5 (enExample) | ||
| AU2018335274A1 (en) | HLA class II–restricted T cell receptors against mutated RAS | |
| JP2019507180A5 (enExample) | ||
| EP4424376A3 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| JP2019519529A5 (enExample) | ||
| EP4282878A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof |